Tesaro
Tesaro[edit | edit source]
Tesaro was a biopharmaceutical company focused on developing and commercializing cancer therapeutics. Founded in 2010, Tesaro was headquartered in Waltham, Massachusetts, and became known for its work in oncology, particularly in the development of treatments for ovarian cancer and other solid tumors.
History[edit | edit source]
Tesaro was founded by former executives of MGI Pharma, including Lonnie Moulder, Mary Lynne Hedley, and Richard Rodgers. The company quickly gained attention in the biopharmaceutical industry due to its strategic focus on oncology and its ability to secure significant funding for its research and development efforts.
In 2018, Tesaro was acquired by GlaxoSmithKline (GSK) for approximately $5.1 billion, marking a significant expansion of GSK's oncology portfolio.
Products[edit | edit source]
Tesaro developed several key products, with a focus on PARP inhibitors and other targeted cancer therapies.
Niraparib (Zejula)[edit | edit source]
Niraparib, marketed under the brand name Zejula, is an oral PARP inhibitor used in the treatment of ovarian cancer. It was approved by the U.S. Food and Drug Administration (FDA) in 2017 for use in patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.
Rolapitant (Varubi)[edit | edit source]
Rolapitant, marketed as Varubi, is a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It was approved by the FDA in 2015 and is used in combination with other antiemetic agents.
Research and Development[edit | edit source]
Tesaro was involved in several clinical trials aimed at expanding the indications for its existing products and developing new therapies. The company's research focused on leveraging its expertise in cancer biology and drug development to create innovative treatments for patients with unmet medical needs.
Acquisition by GlaxoSmithKline[edit | edit source]
In December 2018, GlaxoSmithKline announced its acquisition of Tesaro, which was completed in January 2019. This acquisition was part of GSK's strategy to strengthen its oncology pipeline and enhance its capabilities in the development of cancer therapies.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
